Evidence & policy library
Every pathway is linked to the organizations responsible for the decision.
29 source records
Methodology
Pathway information draws on official regulator, HTA and payer materials. Consult the cited policy for its conditions and effective date, and see Content & use for guidance on applying Atlas to your research.
Matching documents: 34
Market / scopeOfficial evidence recordTypePolicy / reference dateLast checked
APAC
🇵🇭 PhilippinesOfficialeServices entry returned a JavaScript shell; no individual application or product was verifiedNo product-level legal date establishedLatest observed: Access attempt only; content not verified
🇵🇭 PhilippinesOfficialHistorical human-drug registry URL returned 404; do not infer a current CPR statusNo product-level legal date establishedLatest observed: Access attempt only; content not verified
🇵🇭 PhilippinesOfficialSections 27, 28 and 34: provider regulation, affordability and recommendatory HTA; not a product approvalApproved 2019-02-20Latest observed: Selected sections reviewed 2026-10-29
🇵🇭 PhilippinesOfficialCurrent General Track nominator restriction and minor-inclusion conditions; 14 working days is a completion windowUndated live guidance; cited 2022/2023 documents have their own datesLatest observed: Page reviewed on 2026-10-29; not a legal effective date
🇵🇭 PhilippinesOfficialDiscovery index only; use the actual recommendation or circular for a policy conclusionIndex includes separately dated 2026 issuancesLatest observed: Page reviewed on 2026-10-29; not a legal effective date
🇵🇭 PhilippinesOfficialFresh request did not complete; no annual-report conclusion is claimed from this run2024 annual report; publication metadata not reverifiedLatest observed: Access attempt only; content not verified
🇵🇭 PhilippinesOfficialOfficial URL returned 403; use the separate current-topic page and dated adoption records for bounded conclusionsHistorical formulary guideline; current applicability not establishedLatest observed: Access attempt only; content not verified
🇵🇭 PhilippinesOfficialBenefit overview and links, not product-wide full reimbursement or proof of provider stockLive benefits page; individual circular dates applyLatest observed: Page reviewed on 2026-10-29; not a legal effective date
🇵🇭 PhilippinesOfficialBreast-cancer Z example only: eligibility, contracted facility and pre-authorisation; do not generalise to all Z benefitsPC 2024-0007 package FAQ (2024)Latest observed: Selected package conditions reviewed 2026-10-29
🇵🇭 Philippines
OfficialMain pages 3–11: listed preparations, fees, annual benefit, facility, dispensing and subsequent claim rulesPublished 2025-07-30; effectivity clause: 22 days after publicationLatest observed: Read with the separately scoped 2026 supplements
🇵🇭 PhilippinesOfficialSections 17–23 establish price-regulation powers; no current product-level ceiling amount verifiedApproved 2008-06-06Latest observed: Selected price-regulation sections reviewed 2026-10-29
🇵🇭 PhilippinesOfficialUP-PGH one-year framework tender example only; no award, completed delivery or present stock established2026 tender; procurement dates belong to that noticeLatest observed: Page reviewed on 2026-10-29; not a legal effective date
🇵🇭 PhilippinesOfficialFAQ route returned a JavaScript shell; current CSP conclusions use AO 2025-0024 insteadNo product-level legal date establishedLatest observed: Access attempt only; content not verified
🇵🇭 PhilippinesOfficialHistorical framework portal, not itself a new 2026 operative amendment2020 implementing-guideline portal; later issuances separately datedLatest observed: Page reviewed on 2026-10-29; not a legal effective date
🇵🇭 PhilippinesOfficialOfficial PDF URL returned 403; rely only on separately read RA 11223 clauses for the stated general architecture2019 IRR; this copy not read in the fresh runLatest observed: Access attempt only; content not verified
🇵🇭 Philippines
OfficialPC 2026-0002: qualifying >60-day unpaid claims, conditional temporary deactivation, referral and reactivation; not expanded drug entitlementPublished 2026-01-09; FAQ states effectivity 2026-01-24Latest observed: Selected clauses reviewed 2026-10-29; editorial date only
🇵🇭 PhilippinesOfficialPC 2026-0002: qualifying >60-day unpaid claims, conditional temporary deactivation, referral and reactivation; not expanded drug entitlementPublished 2026-01-09; FAQ states effectivity 2026-01-24Latest observed: Selected clauses reviewed 2026-10-29; editorial date only
🇵🇭 PhilippinesOfficialPC 2026-0002: qualifying >60-day unpaid claims, conditional temporary deactivation, referral and reactivation; not expanded drug entitlementPublished 2026-01-09; FAQ states effectivity 2026-01-24Latest observed: Selected clauses reviewed 2026-10-29; editorial date only
🇵🇭 Philippines
OfficialYAKAP clinical and pharmaceutical standards; scope, empanelment and public/private primary-care-provider definitionsPC 2026-0007; specific effectivity must follow its clauseLatest observed: Selected clauses reviewed 2026-10-29; editorial date only
🇵🇭 PhilippinesOfficialYAKAP clinical and pharmaceutical standards; scope, empanelment and public/private primary-care-provider definitionsPC 2026-0007; specific effectivity must follow its clauseLatest observed: Selected clauses reviewed 2026-10-29; editorial date only
🇵🇭 Philippines
OfficialDRG shadow billing revision 2: inpatient data and claim requirements while actual ACR payment continuesPC 2026-0012; inpatient CF5 operational date 2026-08-01Latest observed: Selected clauses reviewed 2026-10-29; editorial date only
🇵🇭 PhilippinesOfficialDRG shadow billing revision 2: inpatient data and claim requirements while actual ACR payment continuesPC 2026-0012; inpatient CF5 operational date 2026-08-01Latest observed: Selected clauses reviewed 2026-10-29; editorial date only
🇵🇭 PhilippinesOfficialDRG shadow billing revision 2: inpatient data and claim requirements while actual ACR payment continuesPC 2026-0012; inpatient CF5 operational date 2026-08-01Latest observed: Selected clauses reviewed 2026-10-29; editorial date only
🇵🇭 Philippines
OfficialPA 2026-0036: accredited inpatient-facility submission requirement; not a new medicine coverage decisionCF5 mandatory for patients discharged from 2026-08-01Latest observed: Selected clauses reviewed 2026-10-29; editorial date only
🇵🇭 PhilippinesOfficialPA 2026-0018 documents GAMOT access delays from provider administrative/readiness requirements; no proof every clinic is readySigned 2026-02-16Latest observed: Selected clauses reviewed 2026-10-29; editorial date only
🇵🇭 Philippines
OfficialPA 2026-0043: GAMOT facility tax documents, withholding and claims cut-off, not a new medicine price or general tax adviceSigned 2026-07-21; claim tax adjustment from 2026-08-01Latest observed: Selected clauses reviewed 2026-10-29; editorial date only
🇵🇭 Philippines
OfficialSelected main-text clauses: authorisation types, applicant eligibility, review routes, decisions, post-authorisation and transition; implementing guidance remains relevantSigned 2024-09-20; effective 2024-12-11 per FDA Advisory 2025-0030Latest observed: Selected clauses reviewed 2026-10-29; editorial date only
🇵🇭 Philippines
OfficialEffectivity and transition only; do not treat consultation drafts as implemented rulesConfirms newspaper publication 2024-11-26 and effectivity 2024-12-11Latest observed: Selected clauses reviewed 2026-10-29; editorial date only
🇵🇭 Philippines
OfficialNamed-patient/institutional restricted use, eligible conditions/status, consent and post-approval duties; not marketing or payer approvalSigned 2025-11-19; official FDA page states effectivity 2025-12-10Latest observed: Selected clauses reviewed 2026-10-29; editorial date only
🇵🇭 PhilippinesOfficialSpecified antibiotic preparations for adult HAP/VAP, pathogen and AMS conditions; adoption evidence is not a local stock or individual treatment confirmationHTAC submission 2026-07-27; SOH decision notification 2026-10-08; posted 2026-10-15Latest observed: Selected clauses reviewed 2026-10-29; editorial date only
🇵🇭 Philippines
OfficialTwo-page PNDF inclusion: exact ingredients, strengths, forms and adult pathogen-specific indications; no universal brand entitlementCircular dated 2026-09-08; not the 2026-10-29 editorial dateLatest observed: Selected clauses reviewed 2026-10-29; editorial date only
🇵🇭 PhilippinesOfficialNew-evidence grounds, exclusion of price-only changes, complete form and recommendation-specific deadlineUndated current instructions; each recommendation sets its own deadlineLatest observed: Selected clauses reviewed 2026-10-29; editorial date only
🇵🇭 Philippines
OfficialSections 3–5: operative new IRR, ongoing pre-effectivity procurements, interim guidelines/forms and standard-form transitionDated 2025-09-18; cites IRR effectivity 2025-02-25 and transition until 2028-05-15Latest observed: Selected clauses reviewed 2026-10-29; editorial date only
🇵🇭 PhilippinesOfficialWithdraws the 31 March 2026 first-edition compilation; directs users to the originally approved/published IRR, not that withdrawn editionPosted 2026-07-31Latest observed: Selected clauses reviewed 2026-10-29; editorial date only
For education only — not regulatory, pricing or legal advice.